Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

Michelle M Mielke, Clinton E. Hagen, Jing Xu, Xiyun Chai, Prashanthi D Vemuri, Val Lowe, David C. Airey, David S Knopman, Rosebud O Roberts, Mary Margaret Machulda, Clifford R Jr. Jack, Ronald Carl Petersen, Jeffrey L. Dage

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Introduction: We examined and compared plasma phospho-tau181 (pTau181) and total tau: (1) across the Alzheimer's disease (AD) clinical spectrum; (2) in relation to brain amyloid β (Aβ) positron emission tomography (PET), tau PET, and cortical thickness; and (3) as a screening tool for elevated brain Aβ. Methods: Participants included 172 cognitively unimpaired, 57 mild cognitively impaired, and 40 AD dementia patients with concurrent Aβ PET (Pittsburgh compound B), tau PET (AV1451), magnetic resonance imaging, plasma total tau, and pTau181. Results: Plasma total tau and pTau181 levels were higher in AD dementia patients than those in cognitively unimpaired. Plasma pTau181 was more strongly associated with both Aβ and tau PET. Plasma pTau181 was a more sensitive and specific predictor of elevated brain Aβ than total tau and was as good as, or better than, the combination of age and apolipoprotein E (APOE). Discussion: Plasma pTau181 may have utility as a biomarker of AD pathophysiology and as a noninvasive screener for elevated brain Aβ.

Original languageEnglish (US)
JournalAlzheimer's and Dementia
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Amyloid
Positron-Emission Tomography
Alzheimer Disease
Brain
Apolipoproteins E
Biomarkers
Magnetic Resonance Imaging

Keywords

  • Alzheimer's disease
  • Amyloid PET
  • Plasma phosphorylated tau
  • Plasma tau
  • Predicting brain amyloid
  • Tau PET

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

@article{6b6ae93f21524b108d36494491bea2b7,
title = "Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography",
abstract = "Introduction: We examined and compared plasma phospho-tau181 (pTau181) and total tau: (1) across the Alzheimer's disease (AD) clinical spectrum; (2) in relation to brain amyloid β (Aβ) positron emission tomography (PET), tau PET, and cortical thickness; and (3) as a screening tool for elevated brain Aβ. Methods: Participants included 172 cognitively unimpaired, 57 mild cognitively impaired, and 40 AD dementia patients with concurrent Aβ PET (Pittsburgh compound B), tau PET (AV1451), magnetic resonance imaging, plasma total tau, and pTau181. Results: Plasma total tau and pTau181 levels were higher in AD dementia patients than those in cognitively unimpaired. Plasma pTau181 was more strongly associated with both Aβ and tau PET. Plasma pTau181 was a more sensitive and specific predictor of elevated brain Aβ than total tau and was as good as, or better than, the combination of age and apolipoprotein E (APOE). Discussion: Plasma pTau181 may have utility as a biomarker of AD pathophysiology and as a noninvasive screener for elevated brain Aβ.",
keywords = "Alzheimer's disease, Amyloid PET, Plasma phosphorylated tau, Plasma tau, Predicting brain amyloid, Tau PET",
author = "Mielke, {Michelle M} and Hagen, {Clinton E.} and Jing Xu and Xiyun Chai and Vemuri, {Prashanthi D} and Val Lowe and Airey, {David C.} and Knopman, {David S} and Roberts, {Rosebud O} and Machulda, {Mary Margaret} and Jack, {Clifford R Jr.} and Petersen, {Ronald Carl} and Dage, {Jeffrey L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jalz.2018.02.013",
language = "English (US)",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

AU - Mielke, Michelle M

AU - Hagen, Clinton E.

AU - Xu, Jing

AU - Chai, Xiyun

AU - Vemuri, Prashanthi D

AU - Lowe, Val

AU - Airey, David C.

AU - Knopman, David S

AU - Roberts, Rosebud O

AU - Machulda, Mary Margaret

AU - Jack, Clifford R Jr.

AU - Petersen, Ronald Carl

AU - Dage, Jeffrey L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: We examined and compared plasma phospho-tau181 (pTau181) and total tau: (1) across the Alzheimer's disease (AD) clinical spectrum; (2) in relation to brain amyloid β (Aβ) positron emission tomography (PET), tau PET, and cortical thickness; and (3) as a screening tool for elevated brain Aβ. Methods: Participants included 172 cognitively unimpaired, 57 mild cognitively impaired, and 40 AD dementia patients with concurrent Aβ PET (Pittsburgh compound B), tau PET (AV1451), magnetic resonance imaging, plasma total tau, and pTau181. Results: Plasma total tau and pTau181 levels were higher in AD dementia patients than those in cognitively unimpaired. Plasma pTau181 was more strongly associated with both Aβ and tau PET. Plasma pTau181 was a more sensitive and specific predictor of elevated brain Aβ than total tau and was as good as, or better than, the combination of age and apolipoprotein E (APOE). Discussion: Plasma pTau181 may have utility as a biomarker of AD pathophysiology and as a noninvasive screener for elevated brain Aβ.

AB - Introduction: We examined and compared plasma phospho-tau181 (pTau181) and total tau: (1) across the Alzheimer's disease (AD) clinical spectrum; (2) in relation to brain amyloid β (Aβ) positron emission tomography (PET), tau PET, and cortical thickness; and (3) as a screening tool for elevated brain Aβ. Methods: Participants included 172 cognitively unimpaired, 57 mild cognitively impaired, and 40 AD dementia patients with concurrent Aβ PET (Pittsburgh compound B), tau PET (AV1451), magnetic resonance imaging, plasma total tau, and pTau181. Results: Plasma total tau and pTau181 levels were higher in AD dementia patients than those in cognitively unimpaired. Plasma pTau181 was more strongly associated with both Aβ and tau PET. Plasma pTau181 was a more sensitive and specific predictor of elevated brain Aβ than total tau and was as good as, or better than, the combination of age and apolipoprotein E (APOE). Discussion: Plasma pTau181 may have utility as a biomarker of AD pathophysiology and as a noninvasive screener for elevated brain Aβ.

KW - Alzheimer's disease

KW - Amyloid PET

KW - Plasma phosphorylated tau

KW - Plasma tau

KW - Predicting brain amyloid

KW - Tau PET

UR - http://www.scopus.com/inward/record.url?scp=85047245015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047245015&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2018.02.013

DO - 10.1016/j.jalz.2018.02.013

M3 - Article

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

ER -